136 related articles for article (PubMed ID: 32886897)
1. Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy.
Ko H; Baghdadi Y; Love C; Sparano JA
J Natl Compr Canc Netw; 2020 Sep; 18(9):1240-1246. PubMed ID: 32886897
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
3.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract][Full Text] [Related]
5. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
6. The value of 18F-FDG PET/CT imaging in breast cancer staging.
Yararbas U; Avci NC; Yeniay L; Argon AM
Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
[TBL] [Abstract][Full Text] [Related]
7. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
9.
Ulaner GA; Juarez J; Riedl CC; Goldman DA
J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
[No Abstract] [Full Text] [Related]
10. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
Hyland CJ; Varghese F; Yau C; Beckwith H; Khoury K; Varnado W; Hirst GL; Flavell RR; Chien AJ; Yee D; Isaacs CJ; Forero-Torres A; Esserman LJ; Melisko ME
J Natl Compr Canc Netw; 2020 Nov; 18(11):1510-1517. PubMed ID: 33152704
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
[TBL] [Abstract][Full Text] [Related]
12. Impact of
Dayes IS; Metser U; Hodgson N; Parpia S; Eisen AF; George R; Blanchette P; Cil TD; Arnaout A; Chan A; Levine MN
J Clin Oncol; 2023 Aug; 41(23):3909-3916. PubMed ID: 37235845
[TBL] [Abstract][Full Text] [Related]
13. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients being Planned Neoadjuvant Treatment.
Simsek ET; Coban E; Atag E; Gungor S; Aker F; Sari M
J Coll Physicians Surg Pak; 2022 Feb; 32(2):181-185. PubMed ID: 35108788
[TBL] [Abstract][Full Text] [Related]
14. Role of
Reddy Akepati NK; Abubakar ZA; Bikkina P
Indian J Nucl Med; 2018; 33(3):190-193. PubMed ID: 29962713
[TBL] [Abstract][Full Text] [Related]
15. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.
Lebon V; Alberini JL; Pierga JY; Diéras V; Jehanno N; Wartski M
J Nucl Med; 2017 Feb; 58(2):252-257. PubMed ID: 27587709
[TBL] [Abstract][Full Text] [Related]
16. PET/CT with
Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Staging PET-CT Scanning Provides Superior Detection of Lymph Nodes and Distant Metastases than Traditional Imaging in Locally Advanced Breast Cancer.
Garg PK; Deo SV; Kumar R; Shukla NK; Thulkar S; Gogia A; Sharma DN; Mathur SR
World J Surg; 2016 Aug; 40(8):2036-42. PubMed ID: 27220508
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
